Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints

Maiken Cavling Arendrup; Michael A Pfaller; Danish Fungaemia Study Group; Helle Krogh Johansen

doi:10.1128/AAC.00355-12

Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints

Maiken Cavling Arendrup, Michael A Pfaller, Danish Fungaemia Study Group, Helle Krogh Johansen

65 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1%) and Candida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.

Original language	English
Journal	Antimicrobial Agents and Chemotherapy
Volume	56
Issue number	7
Pages (from-to)	3965-8
Number of pages	4
ISSN	0066-4804
DOIs	https://doi.org/10.1128/AAC.00355-12
Publication status	Published - 2012

Keywords

Antifungal Agents
Candida
Candida glabrata
Candidiasis
Drug Resistance, Fungal
Echinocandins
Microbial Sensitivity Tests

Access to Document

10.1128/AAC.00355-12

Cite this

Arendrup, M. C., Pfaller, M. A., Danish Fungaemia Study Group, & Johansen, H. K. (2012). Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrobial Agents and Chemotherapy, 56(7), 3965-8. https://doi.org/10.1128/AAC.00355-12

Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. / Arendrup, Maiken Cavling; Pfaller, Michael A; Danish Fungaemia Study Group et al.
In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 7, 2012, p. 3965-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Arendrup, MC, Pfaller, MA, Danish Fungaemia Study Group & Johansen, HK 2012, 'Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints', Antimicrobial Agents and Chemotherapy, vol. 56, no. 7, pp. 3965-8. https://doi.org/10.1128/AAC.00355-12

@article{938f4a3411a3454fa68ddb306d4e8452,

title = "Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints",

abstract = "The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1\%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1\%) and Candida glabrata (33.1\%). The revised breakpoints cannot be safely adopted for these two species.",

keywords = "Antifungal Agents, Candida, Candida glabrata, Candidiasis, Drug Resistance, Fungal, Echinocandins, Microbial Sensitivity Tests",

author = "Arendrup, \{Maiken Cavling\} and Pfaller, \{Michael A\} and \{Danish Fungaemia Study Group\} and Johansen, \{Helle Krogh\}",

year = "2012",

doi = "10.1128/AAC.00355-12",

language = "English",

volume = "56",

pages = "3965--8",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Caspofungin Etest susceptibility testing of Candida species

T2 - risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints

AU - Arendrup, Maiken Cavling

AU - Pfaller, Michael A

AU - Danish Fungaemia Study Group

AU - Johansen, Helle Krogh

PY - 2012

Y1 - 2012

N2 - The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1%) and Candida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.

AB - The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1%) and Candida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.

KW - Antifungal Agents

KW - Candida

KW - Candida glabrata

KW - Candidiasis

KW - Drug Resistance, Fungal

KW - Echinocandins

KW - Microbial Sensitivity Tests

UR - https://www.scopus.com/pages/publications/84862513977

U2 - 10.1128/AAC.00355-12

DO - 10.1128/AAC.00355-12

M3 - Journal article

C2 - 22564836

SN - 0066-4804

VL - 56

SP - 3965

EP - 3968

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

ER -

Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this